Several studies have evaluated the efficacy of PD-1 and PD-L1 inhibitors in different cancers, including lung cancer, renal cancer and malignant melanoma in PD-L1-negative and PD-L1-positive tumors. This evidence concerns the gene CD274 and lung cancer.